NVAX Stock Overview
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
Novavax, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$10.89 |
52 Week High | US$95.34 |
52 Week Low | US$8.75 |
Beta | 1.72 |
1 Month Change | -11.17% |
3 Month Change | -50.81% |
1 Year Change | -88.14% |
3 Year Change | 48.97% |
5 Year Change | -73.18% |
Change since IPO | -86.39% |
Recent News & Updates
Recent updates
COVID-19 remains global health emergency - WHO
Oct 19Novavax spikes ahead of presentations on COVID-19 vaccine portfolio
Oct 10US Supreme Court declines to hear challenge of COVID vaccine mandate for health workers
Oct 03Novavax makes 1M doses of its COVID-19 vaccine available for use in the UK
Sep 27EU clears Novavax's COVID-19 shot for use as a booster dose in adults
Sep 12Novavax wins EU backing for COVID-19 booster shot
Sep 01Novavax: Finding Its Niche
Aug 23Novavax COVID vaccine gets provisional approval in New Zealand as booster shot
Aug 17Novavax Q2: Time To Turn Bullish After The Massive Collapse
Aug 11Bearish: Analysts Just Cut Their Novavax, Inc. (NASDAQ:NVAX) Revenue and EPS estimates
Aug 11Novavax COVID-19 shot is linked to rare cases of heart inflammation – EU agency
Aug 03Novavax gets Japanese regulatory nod for use of its COVID vaccine in teens
Jul 26Serum Institute of India supplies Novavax's COVID vaccine in US
Jul 18Novavax to deliver 3.2M doses of COVID-19 vaccine to U.S.
Jul 11Novavax wins EU nod to use COVID-19 vaccine in adolescents
Jul 05Taiwan to get 504K doses of Novavax COVID vaccine in 1st lot this week
Jun 29Novavax seeks label expansion for COVID-19 shot in Canada
Jun 23The Novavax Vaccine, Finally
Jun 08Is Novavax (NASDAQ:NVAX) Using Debt In A Risky Way?
May 24Novavax: Buying Here Will Not End Well
May 18Novavax: Don't Catch The Falling Knives
May 07Novavax: Management's Revenue Guidance - If It Can Be Trusted - Makes The Bull Case
Apr 21Novavax Stock Forecast: Where Is It Likely Heading By 2025?
Apr 05Novavax: Disappointing Performance Despite Promises - Poor Outlook Ahead
Mar 30Is Novavax Stock A Buy Or Sell As COVID-19 Shot Awaits FDA Approval?
Mar 04Novavax Earnings Preview: Hold On Potential To Deliver Sizeable Vaccine Supply
Feb 24Shareholder Returns
NVAX | US Biotechs | US Market | |
---|---|---|---|
7D | -3.0% | -0.8% | 0.9% |
1Y | -88.1% | 3.9% | -10.9% |
Return vs Industry: NVAX underperformed the US Biotechs industry which returned 3.9% over the past year.
Return vs Market: NVAX underperformed the US Market which returned -10.9% over the past year.
Price Volatility
NVAX volatility | |
---|---|
NVAX Average Weekly Movement | 16.1% |
Biotechs Industry Average Movement | 12.0% |
Market Average Movement | 6.7% |
10% most volatile stocks in US Market | 17.5% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NVAX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: NVAX's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 1,541 | John Jacobs | https://www.novavax.com |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics.
Novavax, Inc. Fundamentals Summary
NVAX fundamental statistics | |
---|---|
Market Cap | US$936.31m |
Earnings (TTM) | -US$1.32b |
Revenue (TTM) | US$1.85b |
0.5x
P/S Ratio-0.7x
P/E RatioIs NVAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NVAX income statement (TTM) | |
---|---|
Revenue | US$1.85b |
Cost of Revenue | US$2.66b |
Gross Profit | -US$814.59m |
Other Expenses | US$507.39m |
Earnings | -US$1.32b |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -15.38 |
Gross Margin | -44.11% |
Net Profit Margin | -71.59% |
Debt/Equity Ratio | -57.3% |
How did NVAX perform over the long term?
See historical performance and comparison